Latest Breaking News On - ஜெநிஂடெக் இன்க் - Page 25 : comparemela.com
Federal Circuit Finds Insufficient Evidence to Establish Standing to Appeal IPR Decisions in Apple Inc v Qualcomm Inc | Haug Partners LLP
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Boston biotech leaders sign letter against voter suppression - San Francisco Business Times
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Emtrain hires Odessa Jenkins as president - Sacramento Business Journal
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
Reata Pharmaceuticals, Inc.April 15, 2021 GMT
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.
“We are excited to welcome Ms. Ruff and Ms. Oliger to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer and President. “They join at a critical point in Reata’s development having just submitted our first New Drug Application for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease caused by Alport syndrome. Both Ms. Ruff and Ms. Oliger bring a wealth of experience that will be invaluable